An Annual Dosing Study of Donanemab in Participants Who Completed Donanemab Study AACM
An Annual Dosing Study of Donanemab in Participants Who Completed Donanemab Study AACM
The main purpose of this study is to determine if participants who previously took donanemab get clinical benefit when they receive annual doses. For each participant, the study will last up to 2.5 years and will include 6 visits.
Inclusion Criteria:
Exclusion Criteria:
LillyTrials@Lilly.com1-317-615-4559
clinical_inquiry_hub@lilly.com
Phoenix, Arizona 85006, United States
602-839-6900
Walnut Creek, California 94598, United States
Springfield, New Jersey 07081, United States
Houston, Texas 77054, United States
Shinjyuku, 160-0017, Japan
81120023812
tabashi City, 173-0015, Japan
714-378-2440
949-753-1663
562-606-5999
951-374-1190
916-434-8230
858-278-3647
714-542-3008
707-521-3830
925-947-2334
305-933-5993
941-708-0005
561-766-2181
904-730-0101
407-500-5252
786-655-8010
305-825-6588
352-383-8222
727-849-4131
407-337-3000
407-705-3471
850-438-1136
386-304-7070
877-791-0656
813-800-5252
352-441-2000
407-916-0060
770-534-5154
678-494-5735
208-685-0600
773-275-3500
877-791-0656
317-537-6099
319-272-2112
337-602-6642
617-699-6927
617-744-1310
586-276-7453
417-328-7781
702-750-000
704-283-7359
937-224-8200
877-791-0656
512-407-8628
409-331-6040
713-486-0536
210-545-4900
253-882-1070
81120023812
81120023812
81120023812
81120023812
81120023812
(787) 798-4592